Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10987819rdf:typepubmed:Citationlld:pubmed
pubmed-article:10987819lifeskim:mentionsumls-concept:C0085828lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0162508lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C1882825lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0036755lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C2266866lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C1707418lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C1704735lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10987819lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10987819pubmed:issue4lld:pubmed
pubmed-article:10987819pubmed:dateCreated2000-10-5lld:pubmed
pubmed-article:10987819pubmed:abstractTextThe daily rhythm in circulating melatonin is driven by a circadian rhythm in the expression of the arylalkylamine N:-acetyltransferase gene in the rat pineal gland. Turning off expression of this gene at the end of night is believed to involve inhibitory transcription factors, among which Fos-related antigen 2 (Fra-2) appears as a good candidate. Circadian rhythms in the expression of three proteins of activating protein-1 (AP-1) complexes, namely, Fra-2, c-Jun, and Jun-D, are shown here to account for circadian variations in AP-1 binding activity. Quantitative variations in the Fra-2 component over the circadian cycle were associated with qualitative variations in protein isoforms. Destruction of the suprachiasmatic nucleus resulted in decreased nocturnal AP-1 activity, showing that AP-1 circadian rhythm is driven by this nucleus. Exposure to light during subjective night and administration of a serotonin 5-HT(1A)/5-HT(7) receptor agonist during subjective day, respectively, induced a 50% decrease and a 50% increase in both AP-1 and Fra-2 expression. These effects were impaired by suprachiasmatic nucleus lesions. These data show that pineal AP-1 binding activity, which results from Fra-2 expression, can be modulated by light and serotonin through the suprachiasmatic nucleus according to a "phase dependence" that is characteristic of the rhythm of clock sensitivity to both zeitgebers.lld:pubmed
pubmed-article:10987819pubmed:languageenglld:pubmed
pubmed-article:10987819pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:citationSubsetIMlld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10987819pubmed:statusMEDLINElld:pubmed
pubmed-article:10987819pubmed:monthOctlld:pubmed
pubmed-article:10987819pubmed:issn0022-3042lld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:DeprezPPlld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:BoslerOOlld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:François-Bell...lld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:BecquetDDlld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:SageDDlld:pubmed
pubmed-article:10987819pubmed:authorpubmed-author:GuillaumondFFlld:pubmed
pubmed-article:10987819pubmed:issnTypePrintlld:pubmed
pubmed-article:10987819pubmed:volume75lld:pubmed
pubmed-article:10987819pubmed:ownerNLMlld:pubmed
pubmed-article:10987819pubmed:authorsCompleteYlld:pubmed
pubmed-article:10987819pubmed:pagination1398-407lld:pubmed
pubmed-article:10987819pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:meshHeadingpubmed-meshheading:10987819...lld:pubmed
pubmed-article:10987819pubmed:year2000lld:pubmed
pubmed-article:10987819pubmed:articleTitleCircadian binding activity of AP-1, a regulator of the arylalkylamine N-acetyltransferase gene in the rat pineal gland, depends on circadian Fra-2, c-Jun, and Jun-D expression and is regulated by the clock's zeitgebers.lld:pubmed
pubmed-article:10987819pubmed:affiliationINSERM U501, Institut Fédératif Jean-Roche, Faculté de Médecine Nord, Université de la Méditerranée, Marseille, France.lld:pubmed
pubmed-article:10987819pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:24516entrezgene:pubmedpubmed-article:10987819lld:entrezgene
entrez-gene:24518entrezgene:pubmedpubmed-article:10987819lld:entrezgene
entrez-gene:25446entrezgene:pubmedpubmed-article:10987819lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10987819lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10987819lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10987819lld:pubmed